このエピソードについて
In this episode of Cholesterol Conversations, Drs. Marc Bonaca, Pam Taub, and Heather Johnson discuss how multiagent therapy can improve the provision of care in the real world. Covered topics include new data from the 2023 ACC Scientific Sessions on the efficacy of novel agents and the role of combination therapy, as well as the importance of shared decision-making and keys to managing high-risk populations.
英語
アメリカ合衆国
文字起こし 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
このポッドキャストの他のエピソード
In this episode of Cholesterol Conversations, join Drs. Neha Pagidipati, Christie Ballantyne, and Gregory Piazza for a roundtable discussion that addresses recent guidance on ASCVD management, current gaps in ASCVD care, patient barriers to LDL-C lowering, and nonstatin therapies to consider for pa…
In this episode of Cholesterol Conversations, host Dr. Heather Johnson, Director of Preventive Cardiology for Women's Services at the Christine E. Lynn Women's Health & Wellness Institute of Baptist Health South Florida, sits down with Dr. Viet T. Le, Associate Professor of Research and Co-Dire…
Your patient's LDL-C is still above goal. What should you do next? Dr. Heather Johnson and Professor Viet Le put the 2026 dyslipidemia guidelines into clinical context and discuss how to use PREVENT-ASCVD, lipoprotein(a), and other risk markers to tailor treatment, set LDL goals, and determine when…
免責: このページに埋め込まれているポッドキャストとアートワークは Vasculearn Network からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。
